Clinical Trial Update: Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A [Phase 2]

View source ↗

Summary

Open-label 48-week extension study of elvucitabine with background ART in HIV-1 patients completed Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Elvucitabine (elvucitabine)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Human Immunodeficiency Virus (HIV)-1 Infection | Phase 2 | Status: COMPLETED